Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130715 · ClinicalTrials.gov registry record · NA
Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery
A NA study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- NA
- Development phase
NCT00130715: Completed NA study, sponsored by Genzyme, a Sanofi Company.
NCT00130715 is a NA study that has completed, run by Genzyme, a Sanofi Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00130715, a NA study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of the study is to evaluate the efficacy of Seprafilm in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm occurring within 30 days postoperatively, and the incidence of abdominopelvic abscess within 6 months postoperatively.
Interventions
- DEVICE Seprafilm Bioresorbable Membrane
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2003-08 |
| Phase | NA |
What the finished NCT00130715 record still lists
NCT00130715 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Seprafilm Bioresorbable Membrane is the first listed.
NCT00130715 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00130715 about?
NCT00130715 is a clinical study titled "Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery". The purpose of the study is to evaluate the efficacy of Seprafilm in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm occurring within 30 days postoperatively, and the incidence of abdominopelvic absce...
What is the current status of trial NCT00130715?
This trial is currently completed. It is a NA study. The study started on 1998-06. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00130715?
The interventions under investigation include: Seprafilm Bioresorbable Membrane (DEVICE).
Who is sponsoring clinical trial NCT00130715?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia